Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Titel:
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Auteur:
Jain, Preetesh Kantarjian, Hagop Alattar, Mona Lisa Jabbour, Elias Sasaki, Koji Gonzalez, Graciela Nogueras Dellasala, Sara Pierce, Sherry Verstovsek, Srdan Wierda, William Borthakur, Gautam Ravandi, Farhad O'Brien, Susan Cortes, Jorge